A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

Exclusion Criteria

• •Participants with any of the following will be excluded from participation in the study:
• •1. Has known systemic hypersensitivity to the mavorixafor drug substance or its inactive ingredients.
• •2. Is pregnant or nursing.
• •3. Has a known history of a positive serology or viral load for human immunodeficiency virus (HIV) or a known history of acquired immunodeficiency syndrome (AIDS).
• •4. Has, at Screening, laboratory tests meeting one or more of the following criteria:
• •* A positive antibody test for hepatitis C virus (HCV), unless documented to have no detectable viral load on 2 independent samples.
• •* A positive test for hepatitis B surface antigen (HBsAg).
• •5. Has any medical or personal condition that, in the opinion of the Investigator, may potentially compromise the safety or compliance of the participant, or may preclude the participant's successful completion of the clinical study.